Every piece of commentary Yazan Al Homsi has written on Rocket Doctor’s August provider network deal opens the same way: with the fact that he is a shareholder. He holds his position through Founders Round Capital, a Vancouver-based venture firm, and has said he would rather state that outright than have a reader assume it. That ordering — disclosure first, analysis second — is consistent across everything he has published on the company.
That ordering is deliberate. Al Homsi draws no salary from Rocket Doctor and holds no board seat or operating role there; what he offers is an outside investor’s read, not an insider’s account, and he treats the distinction as worth naming before any analysis of what the deal itself means. It is a small editorial choice, but one that sets the terms for how much weight a reader should give what follows.
On the substance, Al Homsi has argued that the five-channel agreement — covering commercial insurance, Medicare Advantage, workers’ compensation and auto medical claims — is more consequential as reimbursement infrastructure than as a patient-acquisition headline. More of his disclosure practice and portfolio commentary is available on his website, and his professional background is listed on his LinkedIn profile.
Disclosure does not make an investor’s read correct. It does make it easier for a reader to weigh how much credit to give the analysis, which is precisely the point of stating the conflict up front rather than in a footnote buried at the end of the piece.